Ownership
Private
Employees
~10
Therapeutic Areas
Oncology
Stage
Preclinical
Modalities
Small molecule

MEKanistic Therapeutics General Information

Lead candidate MTX-531 shows significant tumor regression in preclinical models with enhanced safety profile. Selected for NCI's NExT program.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

MTX-531
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to MEKanistic Therapeutics's pipeline data

Book a demo

Key Partnerships

National Cancer Institute (NCI)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

MEKanistic Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view MEKanistic Therapeutics's complete valuation and funding history, request access »

MEKanistic Therapeutics Investors

Invenshure
Investor Type: Venture Capital
Holding: Minority